DrugPatentWatch Database Preview
Drugs in Development Information for LDK378
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug LDK378?
LDK378 is an investigational drug.
There have been 29 clinical trials for LDK378.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are thirty-three US patents protecting this investigational drug and six hundred and fifty-two international patents.
Summary for LDK378
| US Patents | 33 |
| International Patents | 652 |
| US Patent Applications | 82 |
| WIPO Patent Applications | 67 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-12-01) |
| Vendors | 66 |
Recent Clinical Trials for LDK378
| Title | Sponsor | Phase |
|---|---|---|
| Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) | National Cancer Institute (NCI) | Phase 2 |
| A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | Yonsei University | Phase 2 |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for LDK378
Top disease conditions for LDK378
Top clinical trial sponsors for LDK378
US Patents for LDK378
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LDK378 | Start Trial | Polycyclic inhibitor of anaplastic lymphoma kinase | XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) | Start Trial |
| LDK378 | Start Trial | Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same | 2Y-CHEM, LTD. (Shanghai, CN) | Start Trial |
| LDK378 | Start Trial | Inhibitors of ACK1/TNK2 tyrosine kinase | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) | Start Trial |
| LDK378 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| LDK378 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| LDK378 | Start Trial | Pyrimidine compounds | AstraZeneca AB (Sodertalje, SE) | Start Trial |
| LDK378 | Start Trial | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (Basel, CH) IRM LLC (Hamilton, BM) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LDK378
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LDK378 | China | 107108586 | 2034-09-29 | Start Trial |
| LDK378 | European Patent Office | 3202765 | 2034-09-29 | Start Trial |
| LDK378 | Japan | 2017530139 | 2034-09-29 | Start Trial |
| LDK378 | South Korea | 101909404 | 2034-09-29 | Start Trial |
| LDK378 | South Korea | 20170055555 | 2034-09-29 | Start Trial |
| LDK378 | World Intellectual Property Organization (WIPO) | 2016050171 | 2034-09-29 | Start Trial |
| LDK378 | China | 104803908 | 2035-03-26 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
